AJMC® in the Press, March 8, 2024

Articles published by Medriva and BioSpace referenced a study published in the February 2024 issue of The American Journal of Managed Care^® (AJMC^®). The study, “Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications,” examined the clinical development landscape and potential impacts of the Inflation Reduction Act (IRA) of 2022 on high-spend Medicare Part D small molecule drugs, finding that longer development timelines and decreased investments in additional indications could reduce incentives for postapproval research.

An article from Myasthenia Gravis News referenced an article published on AJMC.com, the website of AJMC. The article, “Not So Rare: 300 Million People Worldwide Affected by Rare Diseases,” summarized a study that estimated that approximately 4% of the total world population is affected by a rare disease.

Articles from Medpage Today and Drug Topics^® referenced an article published by AJMC’s sister site, The Center for Biosimilars^®. The article, “FDA Approves First Denosumab Biosimilars,” reported on the FDA approvals for Sandoz’ Wyost and Jubbonti (both denosumab-bddz) to treat osteoporosis and prevent skeletal-related events associated with bone metastases from solid tumors. The biosimilars are the first approved products to reference originator denosumab (Prolia/Xgeva).